retatrutide triple agonist glp-1 gip glucagon phase 2 trial obesity Dual and Gut Peptide Agonists on the Horizon for the Treatment of Type Diabetes and Obesity. An Overview of Preclinical and Clinical Data | Current Reports Unapproved weight loss drug retatrutide

The development of dual GIPRGLP1R coagonists that bind to either one or the other receptor (sequence-mixed dual agonists) has emerged as an innovative therapeutic strategy for obesity and type 2 diabetes

This breakthrough formula fires up GLP-1 production to fend off cravings, especially those carb-loaded temptations

Discover how medications like Ozempic and Wegovy may reduce joint symptoms through weight loss and potential anti-inflammatory effects

It results from the metabolic consequences due to a lack of insulin secretion or impaired insulin activity in diabetes leading to dysregulated pathophysiologic pathways resulting in excessive ketone body formation

In the last 20 years, the emergence of pharmacological treatments for obesity based on gastrointestinal hormones has transformed the ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), initially developed for glycaemic control in patients with type 2 diabetes, have demonstrated significant cardiometabolic benefits